Sentences with phrase «cytarabine in»

ONC201 combined with cytarabine in a Burkitt's lymphoma xenograft model induced tumor growth inhibition that was superior to either agent alone.

«Overall there appears to be a benefit of a fifth course of cytarabine in low - risk patients with AML,» said Kelly D. Getz, PhD, of the Children's Hospital of Philadelphia, who presented the results.

A Phase 1/2, Multicenter, Open - label Study of FT - 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

1) Rituximab was added to the induction as the majority of PCNSL are CD20 + diffuse large B - cell lymphomas (DLBCL) and it was previously shown that the addition of rituximab to CHOP chemotherapy has improved the prognosis in DLBCL outside the brain.8 2) The intraventricular MTX / cytarabine treatment of the Bonn protocol requiring an Ommaya reservoir was replaced by intraspinal administration of liposomal cytarabine in view of the expected lower risk of procedure - related infections.

When used alongside standard chemotherapy agents daunorubicin and cytarabine in a treatment - resistant AML model, 99.7 percent of cancer cells were killed.

Not exact matches

In this study, prior to giving intensive BEAM chemotherapy (which uses carmustine, etoposide, cytarabine, and melphalan), researchers collected stem cells from each patient's blood.

Removal of a fifth course of chemotherapy containing cytarabine resulted in worse overall survival and disease - free survival in pediatric patients with low - risk acute myeloid leukemia (AML), according to the results (abstract 10515) of a pooled analysis of two Children's Oncology Group (COG) trials presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago.

A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine or low - dose cytarabine is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.

A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine (AZA) or low - dose cytarabine (LDAC) is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.

ONC201 synergistically reduced cell viability in combination with cytarabine and 5 - azacytidine in AML cells.

This means steroids in high doses and other drugs such as azathioprine, cytarabine, mycophenolate, cyclosporin, and cyclophosphamide.